Novartis Hemoglobinuria Trial Meets Two Primary Endpoints
24 Outubro 2022 - 2:59AM
Dow Jones News
By Cecilia Butini
Novartis AG said Monday that a study on a drug to treat adult
paroxysmal nocturnal hemoglobinuria, a red blood cell condition,
has met its two primary endpoints.
The trial studied a drug named Iptacopan and established its
superiority to a previously used treatment in helping patients with
debilitating anemia who would normally undergo blood transfusions,
according to the company.
"Iptacopan was well tolerated with a favorable safety profile
consistent with previously reported data," Novartis said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
October 24, 2022 01:44 ET (05:44 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024